DBP International AB has together with Bio Vitos Medical Ltd signed an agreement on scientific, technical and sales collaboration with Belarusian Academpharm
Double Bond Pharmaceutical International AB (publ) (“DBP”) has signed a 3-way agreement with Bio Vitos Medical Ltd (“Bio Vitos”) and Academpharm (Republic of Belarus) concerning a technical and scientific collaboration.
The purpose of the agreement between Academpharm and Bio Vitos is to get access to its products on the markets in the Eurasian Economic Union (EaEU). Bio Vitos has a line of more than 40 Omega 3 products from North Norway, containing vitamins, minerals, iron succinate etc.
The Bio Vitos agreement with Academpharm, gives access to the countries: Belarus, Russia, Kazakhstan, Turkmenistan, Azerbaijan, and Armenia, a total of markets with almost 200 million inhabitants.
As previously announced, DBP owns 20 % of Bio Vitos: https://mb.cision.com/Main/12720/3440256/1486281.pdf
About BioVitos: BioVitos is an English limited company, specializing in development and sale of dietary supplements, based on high quality Omega 3 salmon oil from North Norway.
Bio Vitos also has Omega 3 products added with cannabis oil (CBD).
Bio Vitos is in preparation for an application to be part of the Danish Medical Agency's pilot program for medical cannabis.
29.39 % of Bio Vitos is owned by Craven House Capital Plc ("CRV") which is listed on the London Stock Exchange's AIM list.
About Academpharm: Academpharm is a dynamically developing high-tech state-owned pharmaceutical company for production and distribution of high-quality drug substances and biologically active additives.
Belarus State Academpharm is focused on the pharmaceutical industry within the Eurasian Economic Union (EaEU), the European Union (EU) and the US market. https://academpharm.by/en/
____________________________________________________________________
Full Company Name: Double Bond Pharmaceutical International AB (publ)
Corporate identity: 556991-6082
Stock short name: DBP B
Share ISIN code: SE0007185525
For more info, contact
Igor Lokot, CEO
Homepage: http://www.doublebp.com/
E-mail: info@doublebp.com
Follow us on LinkedIn and Twitter!
____________________________________________________________________
Information about Double Bond Pharmaceutical International AB
DBP is a pharmaceutical company with the primary focus on the development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumors, in October 2015, and was granted Orphan Drug Designation status by EMA in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in the EU and globally and has a working name SI-053 in the DBP pipeline.